NCT05410821
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +16 more
- Locations
-
- The First Affiliated Hospital of Xiamen University Xiamen, China
Clinical trial condition
Refractory Thyroid Gland Carcinoma
Explore clinical trials studying Refractory Thyroid Gland Carcinoma. Study availability and eligibility vary by location and protocol.
6 public trials
0 recruiting studies
Refractory Thyroid Gland Carcinoma trial results
NCT00381641
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +37 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Decatur Memorial Hospital Decatur, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
- Ingalls Memorial Hospital Harvey, Illinois, United States
Active, Not Recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Endocrine Gland Neoplasms, Endocrine System Diseases, +102 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
NCT03914300
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +20 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
Active, Not Recruiting
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT02152995
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +23 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
Active, Not Recruiting
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
NCT04061980
- Conditions
- BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Endocrine Gland Neoplasms, +11 more
- Locations
-
- Providence Portland Medical Center Portland, Oregon, United States